MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Collegium Pharmaceutical DIO Ratio 2011-2026 | COLL
Annual DIO Ratio Collegium Pharmaceutical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 181 | 148 | 59.8 | 45.8 | 47.7 | 35.4 | 18.2 | 17.2 | 255 | 2.26 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.26 K | 17.2 | 306 |
Quarterly DIO Ratio Collegium Pharmaceutical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 43.4 | 43.2 | 41.3 | - | 48.1 | - | - | - | 48.7 | 43.6 | 53.8 | - | 43.3 | 51.4 | 126 | 55.3 | 51.5 | 49 | 44.2 | 44.5 | 46 | 48 | 30.7 | 17.9 | 18.8 | 18.1 | 16.2 | 24 | 15.5 | 15.2 | 10.2 | 151 | 299 | 287 | 385 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 385 | 10.2 | 72.3 |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
512 | - | - | $ 40.3 B |  USA |
 |
Codexis
CDXS
|
50.2 | $ 1.02 | 1.49 % | $ 74.9 M | USA |
 |
Cerus Corporation
CERS
|
213 | $ 2.6 | 1.37 % | $ 480 M | USA |
 |
Midatech Pharma plc
MTP
|
40.6 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Cellectis S.A.
CLLS
|
23.3 | $ 3.87 | -0.39 % | $ 116 M |  France |
 |
Acorda Therapeutics
ACOR
|
345 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
136 | - | 4.01 % | $ 150 M |  Canada |
 |
Институт стволовых клеток человека
ISKJ
|
275 | - | - | - |  Russia |
 |
Albireo Pharma
ALBO
|
26.1 | - | -0.23 % | $ 916 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
356 | $ 36.14 | 1.23 % | $ 3.75 B | USA |
 |
Amarin Corporation plc
AMRN
|
292 | $ 13.98 | 1.27 % | $ 5.7 B |  Irlanda |
 |
Catalyst Pharmaceuticals
CPRX
|
119 | $ 23.77 | 2.99 % | $ 2.91 B | USA |
 |
Aeterna Zentaris
AEZS
|
55.6 | - | 5.93 % | $ 314 M | Canada |
 |
CorMedix
CRMD
|
180 | $ 7.16 | 0.42 % | $ 364 M | USA |